Progress in TB drug development and what is still needed

Tuberculosis

Volumn 83, Issue 1-3, 2003, Pages 201-207

  Duncan, Ken ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; BIOLOGICAL MARKER; NITROIMIDAZOLE DERIVATIVE; TUBERCULOSTATIC AGENT;

BACTERIAL GENOME; BACTERIAL STRAIN; CONFERENCE PAPER; CONVALESCENCE; DRUG EFFICACY; DRUG RESEARCH; DRUG TARGETING; GENE FUNCTION; GENE SEQUENCE; GENOMICS; MODEL; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; SCREENING; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 0038519673     PISSN: 14729792     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1472-9792(02)00076-8     Document Type: Conference Paper

References (18)

1. The Tuberculosis Trials Consortium. Rifapentine, isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 2002;360:528-34.
2. Tuberculosis Research Centre, Chennai. Shortening short course chemotherapy: a randomised clinical trial for treatment of smear positive pulmonary tuberculosis with regimens using ofloxacin in the intensive phase. Ind J Tuberc 2002;49:27-38.
3. O'Brien RJ, et al. Scientific blueprint for TB drug development. Tuberculosis 2001;81 (Supplement 1).
4. Global Alliance for TB Drug Development. The economics of TB drug development.
5. http://csdd.tufts.edu
6. Suarez S, O'Hara P, Kazantseva M, et al. Airways delivery of rifampicin microparticles for the treatment of tuberculosis. J Antimicrob Chemother 2001;48:431-4.
7. http://www.sequella.com
8. Stover CK, Warrener P, VanDanter DR, et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 2000;405:962-6.
9. Cole ST, Brosch R, Parkhill J, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998;393:537-44.
10. Fleischmann RD, Alland D, Eisen JA, et al. Whole-genome comparison of Mycobacterium tuberculosis clinical and laboratory strains. J Bacteriol 2002;184: 5479-90.
11. http://www.sanger.ac.uk/Projects/M_bovis/
12. http://www.tigr.org/tdb/mdb/mdbinprogress.html
13. Cole ST, Eiglemeier K, Parkhill J, et al. Massive gene decay in the leprosy bacillus. Nature 2001;409:1007-11.
14. McAdam RA, Quan S, Smith DA, et al. Characterisation of a Mycobacteriurn tuberculosis H37Rv transposon library reveals insertions in 351 ORFs and mutants with altered virulence. Microbiology 2002;148:2975-86.
15. Betts JC, Lukey PT, McAdam RA, Duncan K. Gene expression profiling of Mycobacterium tuberculosis during nutrient starvation. Mol Micro 2002;43:717-31.
16. Fenhalls G, Stevens L, Moses L, et al. In situ detection of Mycobacteriurn tuberculosis transcripts in human lung granulomas reveals differential gene expression in necrotic lesions. Infect Immun 2002;70:6330-8.
17. Oishi H, Noto T, Sasaki H, et al. Thiolactomycin, a new antibiotic. I. Taxonomy of the producing organism, fermentation and biological properties. J Antibiot 1982;35:391-5.
18. http://www.doe-mbi.ucla.edu/TB/index.php